NovaBridge Biosciences to Participate in September Investor Conferences
NovaBridge Biosciences (Nasdaq: NBP) announced that CEO Srishti Gupta will present at two investor conferences in September 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced that CEO Srishti Gupta will present at two investor conferences in September 2026. She will join fireside chats and one-on-one meetings at the Cantor 2026 Global Healthcare Conference on September 10, 2026 at 1:00 PM ET and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 9:30 AM ET. Webcasts of both sessions will be available on NovaBridge’s News & Events webpage for 90 days.
Details
News Market Reaction – NBP
On Aug 27, the day this news came out, NBP closed 1.07% above the previous close. Our momentum scanner recorded 4 alerts in the available session data.
Data tracked by StockTitan Argus for the Aug 27 session.
Key Figures
- First conference date
- September 10, 2026
- Cantor 2026 Global Healthcare Conference
- First conference time
- 1:00 PM ET
- Cantor 2026 Global Healthcare Conference
- Second conference date
- September 14, 2026
- H.C. Wainwright 28th Annual Global Investment Conference
- Second conference time
- 9:30 AM ET
- H.C. Wainwright 28th Annual Global Investment Conference
- Webcast availability
- 90 days
- News & Events page webcast access
Historical Context
-
Net loss widened despite pipeline progress and reported liquidity supporting milestones.
-
Scheduled the first-half results webcast and corporate update for August 20, 2026.
-
Set the shareholder meeting, voting record date, and proxy deadlines for September.
-
Named Srishti Gupta CEO and board member effective July 1, 2026.
-
Received FDA Fast Track Designation for givastomig in first-line gastric cancer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:
Conference details:
Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Monday, September 14, 2026
Time: 9:30 AM ET
Webcast Link: Here
Webcasts of the Fireside chats will be accessible in the News & Events page of the NovaBridge website for 90 days.
About NovaBridge
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.
NovaBridge’s portfolio is led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
Bill Begien, VP, Investor Relations
bill.begien@novabridge.com
Jessica Zhang, Director, Public Relations
jessica.zhang@novabridge.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.